RT Journal Article
SR Electronic
T1 Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e234955
DO 10.1136/bcr-2020-234955
VO 13
IS 11
A1 Ammar, Abdalla A
A1 Ammar, Mahmoud A
A1 Owusu, Kent
A1 Gilmore, Emily J
YR 2020
UL http://casereports.bmj.com/content/13/11/e234955.abstract
AB Diagnosis and management of status epilepticus (SE), including non-convulsive status epilepticus (NCSE), is challenging, with a reported 30%–50% of epilepticus patients not responding to available antiseizure medications (ASMs). Injectable benzodiazepines, fosphenytoin, valproate, levetiracetam, lacosamide and phenobarbital are commonly used for treating SE. Brivaracetam, a new ASM, with higher affinity and greater selectivity for the synaptic vesicle glycoprotein 2A than levetiracetam, has been approved as monotherapy or adjunct for treatment of focal onset seizures. Brivaracetam may have a role in the management of SE. However, limited data exist on brivaracetam’s efficacy in SE. We describe a patient case with focal NCSE refractory to levetiracetam, fosphenytoin, lacosamide and valproate who demonstrated clinical and electrographic improvement on continuous electroencephalography monitoring after brivaracetam administration.